Labrosse, J.; Morel, C.; Lam, T.; Laas, E.; Feron, J.-G.; Coussy, F.; Lae, M.; Reyal, F.; Hamy, A.-S.
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancers 2021, 13, 235.
https://doi.org/10.3390/cancers13020235
AMA Style
Labrosse J, Morel C, Lam T, Laas E, Feron J-G, Coussy F, Lae M, Reyal F, Hamy A-S.
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancers. 2021; 13(2):235.
https://doi.org/10.3390/cancers13020235
Chicago/Turabian Style
Labrosse, Julie, Charlotte Morel, Thanh Lam, Enora Laas, Jean-Guillaume Feron, Florence Coussy, Marick Lae, Fabien Reyal, and Anne-Sophie Hamy.
2021. "The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer" Cancers 13, no. 2: 235.
https://doi.org/10.3390/cancers13020235
APA Style
Labrosse, J., Morel, C., Lam, T., Laas, E., Feron, J.-G., Coussy, F., Lae, M., Reyal, F., & Hamy, A.-S.
(2021). The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancers, 13(2), 235.
https://doi.org/10.3390/cancers13020235